Gender-dependent physiological implications of combined PAI-1 and TIMP-1 gene deficiency characterized in a mouse model

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 293, Issue 4, 2007, Pages

  Harslund, Jakob ^a   Nielsen, Ole Lerberg ^a   Brünner, Nils ^a   Offenberg, Hanne ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Blood leukocyte count; Body weight; Gene expression; Plasminogen activator inhibitor type 1; Tissue inhibitor of metalloproteinase type 1

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; EMBRYO DEVELOPMENT; FEMALE; GENDER; GENE EXPRESSION; GENOTYPE; HISTOLOGY; IMMUNITY; KNOCKOUT MOUSE; LEUKOCYTE COUNT; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; UPREGULATION;

ANIMALS; FEMALE; LEUKOCYTE COUNT; LEUKOCYTES; MALE; MICE; MICE, KNOCKOUT; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMERASE CHAIN REACTION; SEX CHARACTERISTICS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 35148820652     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00380.2007     Document Type: Article

References (45)

1. Bajou K, Maillard C, Jost M, Lijnen RH, Gils A, Declerck P, Carmeliet P, Foidart JM, Noel A. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 23: 6986-6990, 2004.
2. Boeker KHW, Haberkorn CI, Michels D, Flemming P, Manns MP, Lichtinghagen R. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta 316: 71-81, 2002.
3. Carmeliet P, Kieckens L, Schoonjans L, Ream B, Vannuffelen A, Prendergast G, Cole M, Bronson R, Collen D, Mulligan RC. Plasminogen-activator inhibitor-1 gene deficient mice. 1. Generation by homologous recombination and characterization. J Clin Invest 92: 2746-2755, 1993.
4. Carmeliet P, Stassen JM, Schoonjans L, Ream B, Vandenoord JJ, Demol M, Mulligan RC, Collen D. Plasminogen-activator inhibitor-1 gene deficient mice. 2. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 92: 2756-2760, 1993.
5. Chakraborty C, Gleeson LM, McKinnon T, Lala PK. Regulation of human trophoblast migration and invasiveness. Can J Physiol Pharmacol 80: 116-124, 2002.
6. Chromek M, Tullus K, Lundahl J, Brauner A. Tissue inhibitor of metalloproteinase 1 activates normal human granulocytes, protects them from apoptosis, and blocks their transmigration during inflammation. Infect Immun 72: 82-88, 2004.
7. Coulam CB, Jeyendran RS, Fishel LA, Roussev R. Multiple thrombophilic gene mutations are risk factors for implantation failure. Reprod Biomed Online 12: 322-327, 2006.
8. Crandall DL, Quinet EM, El AS, Hreha AL, Leik CE, Savio DA, Juhan-Vague I, Alessi MC. Modulation of adipose tissue development by pharmacological inhibition of PAI-1. Arterioscler Thromb Vasc Biol 26: 2209-2215, 2006.
9. Davis GE, Allen KAP, Salazar R, Maxwell SA. Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. J Cell Sci 114: 917-930, 2001.
10. Demeulemeester D, Scroyen I, Voros G, Snoeys J, De Geest B, Collen D, Lijnen HR. Overexpression of tissue inhibitor of matrix metalloproteinases-I (TIMP-1) in mice does not affect adipogenesis or adipose tissue development. Thromb Haemost 95: 1019-1024, 2006.
11. Fujisaki K, Tanabe N, Suzuki N, Mitsui N, Oka H, Ito K, Maeno M. The effect of IL-1 alpha on the expression of matrix metalloproteinases, plasminogen activators, and their inhibitors in osteoblastic ROS 17/2.8 cells. Life Sci 78: 1975-1982, 2006.
12. Green KA, Lund LR. ECM degrading proteases and tissue remodelling in the mammary gland. Bioessays 27: 894-903, 2005.
13. Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, Sorensen S, Overgaard J, Lilja H, Harris A, Murphy G, Brunner N. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 8: 156-164, 2002.
14. Irigoyen JP, Munoz-Canoves P, Montero L, Koziczak M, Nagamine Y. The plasminogen activator system: biology and regulation. Cell Mol Life Sci 56: 104-132, 1999.
15. Kastl SP, Speidl WS, Kaun C, Rega G, Assadian A, Weiss TW, Valent P, Hagmueller GW, Maurer G, Huber K, Wojta J. The complement component C5a induces the expression of plasminogen activator inhibitor-1 in human macrophages via NF-kappa B activation. J Thromb Haemost 4: 1790-1797, 2006.
16. Knittel T, Mehde M, Kobold D, Saile B, Dinter C, Ramadori G. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1. J Hepatol 30: 48-60, 1999.
17. Kralisch S, Bluher M, Tonjes A, Lossner U, Paschke R, Stumvoll M, Fasshauer M. Tissue inhibitor of metalloproteinase-1 predicts adiposity in humans. Eur J Endocrinol 156: 257-261, 2007.
18. Lee JH, Lee KH, Lee JH, Kim S, Seol M, Park CJ, Chi HS, Kang W, Kim ST, Kim WK, Lee JS. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide. Br J Haematol 118: 1087-1094, 2002.
19. Lee MM, Yoon BJ, Osiewicz K, Preston M, Bundy B, van Heeckeren AM, Werb Z, Soloway PD. Tissue inhibitor of metalloproteinase 1 regulates resistance to infection. Infect Immun 73: 661-665, 2005.
20. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 86: 324-333, 2001.
21. Lijnen HR, Alessi MC, Van Hoef B, Collen D, Juhan-Vague I. On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. J Thromb Haemost 3: 1174-1179, 2005.
22. Lijnen HR, Demeulemeester D, Van Hoef B, Collen D, Maquoi E. Deficiency of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) impairs nutritionally induced obesity in mice. Thromb Haemost 89: 249-255, 2003.
23. Lijnen HR, Van Hoef B, Soloway P, Collen D. Plasminogen/plasmin system function in mice deficient in stromelysin-1 (MMP-3) or in tissue inhibitor of metalloproteinases type-1 (TIMP-1). Fibrinolysis Proteolysis 12: 1-8, 1998.
24. Liu YX, Gao F, Wei P, Chen XL, Gao HJ, Zou RJ, Siao LJ, Xu FH, Feng Q, Liu K, Hu ZY. Involvement of molecules related to angiogenesis, proteolysis and apoptosis in implantation in rhesus monkey and mouse. Contraception 71: 249-262, 2005.
25. Lund LR, Romer J, Bugge TH, Nielsen BS, Frandsen TL, Degen JL, Stephens RW, Dano K. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J 18: 4645-4656, 1999.
26. Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH, Vaughan DE, Fogo AB. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53: 336-346, 2004.
27. Macfelda K, Weiss TW, Kaun C, Breuss JM, Zorn G, Oberndorfer U, Voegele-Kadletz M, Huber-Beckmann R, Ullrich R, Binder BR, Losert UM, Maurer G, Pacher R, Huber K, Wojta J. Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes. J Mol Cell Cardiol 34: 1681-1691, 2002.
28. Marshall LJ, Ramdin LS, Brooks T, DPhil PC, Shute JK. Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. J Immunol 171: 2057-2065, 2003.
29. Meigs JB, O'Donnell CJ, Tofler GH, Benjamin EJ, Fox CS, Lipinska I, Nathan DM, Sullivan LM, D'Agostino RB, Wilson PW. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes 55: 530-537, 2006.
30. Mertens I, Verrijken A, Michiels JJ, Van der Planken M, Ruige JB, Van Gaal LF. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes 30: 1308-1314, 2006.
31. Monjo M, Rodriguez AM, Palou A, Roca P. Direct effects of testosterone, 17 beta-estradiol, and progesterone on adrenergic regulation in cultured brown adipocytes: potential mechanism for gender-dependent thermogenesis. Endocrinology 144: 4923-4930, 2003.
32. Morange PE, Lijnen HR, Alessi MC, Kopp F, Collen D, Juhan-Vague I. Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol 20: 1150-1154, 2000.
33. Nothnick WB. Disruption of the tissue inhibitor of metalloproteinase-1 gene results in altered reproductive cyclicity and uterine morphology in reproductive-age female mice. Biol Reprod 63: 905-912, 2000.
34. Offenberg H, Thomsen PD. Functional challenge affects aquaporin rnRNA abundance in mouse blastocysts. Mol Reprod Dev 71: 422-430, 2005.
35. Oishi K, Ohkura N, Ishida N. Adrenal gland-dependent augmentation of plasminogen activator inhibitor-1 expression in streptozotocin-induced diabetic mice. J Thromb Haemost 4: 1566-1574, 2006.
36. Okamoto I, Otte AP, Allis CD, Reinberg D, Heard E. Epigenetic dynamics of imprinted X inactivation during early mouse development. Science 303: 644-649, 2004.
37. Reichenstein M, Reich R, LeHoux JG, Hanukoglu I. ACTH induces TIMP-1 expression and inhibits collagenase in adrenal cortex cells. Mol Cell Endocrinol 215: 109-114, 2004.
38. Renckens R, Roelofs JJTH, de Waard V, Florquin S, Lijnen HR, Carmeliet P, van der Poll T. The role of plasminogen activator inhibitor type 1 in the inflammatory response to local tissue injury. J Thromb Haemost 3: 1018-1025, 2005.
39. Rhee JS, Diaz R, Korets L, Hodgson JG, Coussens LM. TIMP-1 alters susceptibility to carcinogenesis. Cancer Res 64: 952-961, 2004.
40. Schrohl AS, Christensen IJ, Pedersen AN, Jensen V, Mouridsen H, Murphy G, Foekens JA, Brunner N, Holten-Andersen MN. Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol Cell Proteomics 2: 164-172, 2003.
41. Senzaki H, Kobayashi T, Nagasaka H, Nakano H, Kyo S, Yokote Y, Sasakid N. Plasminogen activator inhibitor-1 in patients with Kawasaki disease: diagnostic value for the prediction of coronary artery lesion and implication for a new mode of therapy. Pediatr Res 53: 983-988, 2003.
42. Soloway PD, Alexander CM, Werb Z, Jaenisch R. Targeted mutagenesis of Timp-1 reveals that lung tumor invasion is influenced by Timp-1 genotype of the tumor but not by that of the host. Oncogene 13: 2307-2314, 1996.
43. Teesalu T, Hinkkanen AE, Vaheri A. Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice. Am J Pathol 159: 2227-2237, 2001.
44. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827-839, 2003.
45. Watanabe H, Numata K, Ito T, Takagi K, Matsukawa A. Innate immune response in Th1- and Th2-dominant mouse strains. Shock 22: 460-466, 2004.